Another phase III trial, J-ALEX, enrolled 207 ALK inhibitor-naive Japanese patients with ALK-positive NSCLC, also proved that alectinib as a first-line treatment achieved a higher objective response rate compared to crizotinib (92% vs. 79%) (54). Here, ALK is linked to non-small cell lung carcinoma.